February 5, 2018 / 10:18 PM / 10 months ago

BRIEF-Roche Says Late-stage Study Shows Genentech's Tecentriq And Avastin Reduced The Risk Of Disease Worsening Or Death By 26 Pct In Certain People With Advanced Kidney Cancer

Feb 5 (Reuters) - Roche Holding Ag:

* PHASE III IMMOTION151 STUDY SHOWED GENENTECH’S TECENTRIQ (ATEZOLIZUMAB) AND AVASTIN (BEVACIZUMAB) REDUCED THE RISK OF DISEASE WORSENING OR DEATH BY 26 PERCENT IN CERTAIN PEOPLE WITH ADVANCED KIDNEY CANCER

* GENENTECH SAYS TECENTRIQ AND AVASTIN MET CO-PRIMARY ENDPOINT

* GENENTECH - INITIAL OBSERVATIONS FROM CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN OVERALL STUDY POPULATION WERE “ENCOURAGING, BUT ARE STILL IMMATURE”

* GENENTECH - RATE OF TREATMENT-RELATED GRADE 3-4 ADVERSE EVENTS LOWER WITH TECENTRIQ & AVASTIN COMBINATION VERSUS SUNITINIB IN ALL TREATED PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below